{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:01:15Z","timestamp":1786114875292,"version":"build-2736575974"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100020407","name":"Tata Medical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004101","name":"Lady Tata Memorial Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004101","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012117","name":"Lady Tata Memorial Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012117","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.radonc.2026.111576","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T23:45:50Z","timestamp":1778888750000},"page":"111576","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Impact of ultrahypofractionated adjuvant regional nodal radiotherapy on patient-reported quality of life: the HYPORT adjuvant trial (NCT03788213)"],"prefix":"10.1016","volume":"220","author":[{"given":"Santam","family":"Chakraborty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7402-8645","authenticated-orcid":false,"given":"Sanjoy","family":"Chatterjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9347-1802","authenticated-orcid":false,"given":"Patricia.","family":"S","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Punita","family":"Lal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8387-9716","authenticated-orcid":false,"given":"Rajesh","family":"Balakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8760-3458","authenticated-orcid":false,"given":"Rosina","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Selvamani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shagun","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirley","family":"Lewis Salins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2026.111576_b0005","first-page":"287","article-title":"Global burden of female breast cancer: new estimates in 2022, temporal trend and future projections up to 2050 based on the latest release from GLOBOCAN","volume":"5","author":"Zhang","year":"2025","journal-title":"J Natl Cancer Cent"},{"key":"10.1016\/j.radonc.2026.111576_b0010","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s10549-017-4118-7","article-title":"Hypofractionated whole breast radiotherapy in breast conservation for early-stage breast cancer: a systematic review and meta-analysis of randomized trials","volume":"162","author":"Valle","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.radonc.2026.111576_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(20)30932-6","article-title":"Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial","author":"Murray Brunt","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2026.111576_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2025.110915","article-title":"Patient- and clinician-assessed five-year normal tissue effects following one-week versus three-week axillary radiotherapy for breast cancer: results from the phase III FAST-Forward trial randomised nodal sub-study","volume":"207","author":"Brunt","year":"2025","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111576_b0025","unstructured":"XXXXXXX."},{"key":"10.1016\/j.radonc.2026.111576_b0030","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s00066-020-01744-3","article-title":"Moderate hypofractionation remains the standard of care for whole-breast radiotherapy in breast cancer: considerations regarding FAST and FAST-Forward","volume":"197","author":"Krug","year":"2021","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.radonc.2026.111576_b0035","unstructured":"XXXXXXX."},{"key":"10.1016\/j.radonc.2026.111576_b0040","unstructured":"XXXXXXX."},{"key":"10.1016\/j.radonc.2026.111576_b0045","unstructured":"XXXXXXX."},{"key":"10.1016\/j.radonc.2026.111576_b0050","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.radonc.2013.09.024","article-title":"The Cambridge post-mastectomy radiotherapy (C-PMRT) index: a practical tool for patient selection","volume":"110","author":"Mukesh","year":"2014","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111576_b0055","first-page":"172","article-title":"Validation of EORTC quality-of-life questionnaire in Indian women with operable breast cancer","volume":"18","author":"Parmar","year":"2005","journal-title":"Natl Med J India"},{"key":"10.1016\/j.radonc.2026.111576_b0060","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1023\/A:1015083713014","article-title":"Quality of life in breast cancer patients: validation of a FACT-B Malayalam version","volume":"11","author":"Pandey","year":"2002","journal-title":"Qual Life Res"},{"key":"10.1016\/j.radonc.2026.111576_b0065","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1200\/JCO.1997.15.3.974","article-title":"Reliability and validity of the functional assessment of cancer therapy-breast quality-of-life instrument","volume":"15","author":"Brady","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111576_b0070","article-title":"EORTC QLQ-C30 scoring manual. quality of life unit, european organization for research and therapy","author":"Fayers","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2026.111576_b0075","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ejca.2023.04.027","article-title":"Minimally important differences for interpreting EORTC QLQ-C30 change scores over time: a synthesis across 21 clinical trials involving nine different cancer types","volume":"188","author":"Musoro","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.radonc.2026.111576_b0080","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1002\/sim.1783","article-title":"Sample sizes for clinical trials with normal data","volume":"23","author":"Julious","year":"2004","journal-title":"Stat Med"},{"key":"10.1016\/j.radonc.2026.111576_b0085","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.jclinepi.2004.01.012","article-title":"A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale","volume":"57","author":"Eton","year":"2004","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.radonc.2026.111576_b0090","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2013a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"10.1016\/j.radonc.2026.111576_b0095","doi-asserted-by":"crossref","first-page":"e683","DOI":"10.1016\/S1470-2045(25)00520-0","article-title":"SISAQOL-IMI consensus-based guidelines to design, analyse, interpret, and present patient-reported outcomes in cancer clinical trials","volume":"26","author":"Amdal","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2026.111576_b0100","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1245\/s10434-023-14277-7","article-title":"Risk factors for breast cancer-related lymphedema: an umbrella review","volume":"31","author":"Shen","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.radonc.2026.111576_b0105","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.ijrobp.2014.12.029","article-title":"Radiation therapy risk factors for development of lymphedema in patients treated with regional lymph node irradiation for breast cancer","volume":"91","author":"Chandra","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111576_b0110","doi-asserted-by":"crossref","first-page":"4251","DOI":"10.21105\/joss.04251","article-title":"rbmi: a R package for standard and reference-based multiple imputation methods","volume":"7","author":"Gower-Page","year":"2022","journal-title":"J Open Source Softw"},{"key":"10.1016\/j.radonc.2026.111576_b0115","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1001\/jama.2025.7420","article-title":"Tipping point analysis: assessing the potential impact of missing data: assessing the potential impact of missing data","volume":"334","author":"Liu","year":"2025","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.radonc.2026.111576_b0120","doi-asserted-by":"crossref","unstructured":"Coles CE, Griffin CL, Kirby AM, Haviland JS, Titley JC, Benstead K, et al. Dose escalated simultaneous integrated boost radiotherapy for women treated by breast conservation surgery for early breast cancer: 3-year adverse effects in the IMPORT HIGH trial (CRUK\/06\/003) 2018.","DOI":"10.1158\/1538-7445.SABCS18-GS4-05"},{"key":"10.1016\/j.radonc.2026.111576_b0125","article-title":"Late normal tissue effects in the arm and shoulder following lymphatic radiotherapy: results from the UK START (Standardisation of Breast Radiotherapy) trials","author":"Haviland","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111576_b0130","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S1470-2045(24)00661-2","article-title":"Single-modality endocrine therapy versus radiotherapy after breast-conserving surgery in women aged 70 years and older with luminal A-like early breast cancer (EUROPA): a preplanned interim analysis of a phase 3, non-inferiority, randomised trial","volume":"26","author":"Meattini","year":"2025","journal-title":"Lancet Oncol"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814026004159?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814026004159?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T22:05:07Z","timestamp":1785967507000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814026004159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":26,"alternative-id":["S0167814026004159"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2026.111576","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of ultrahypofractionated adjuvant regional nodal radiotherapy on patient-reported quality of life: the HYPORT adjuvant trial (NCT03788213)","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2026.111576","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111576"}}